THE MEDICINES PATENT POOL AND GILEAD SCIENCES SIGN LICENCE FOR BICTEGRAVIR
The MPP announced on 4 October 2017 a licence with Gilead Sciences for bictegravir (BIC), now under review in the United States and the European Union as part of a once-daily, single-tablet HIV regimen.
BRISTOL-MYERS SQUIBB, MEDICINES PATENT POOL EXTEND LICENCE FOR ATAZANAVIR TO 122 DEVELOPING COUNTRIES
The MPP has signed an extension of its licensing agreement with biopharmaceutical company Bristol-Myers Squibb (BMS) to further increase access to atazanavir (ATV), part of the World Health Organization-preferred second-line treatment for adults and children.
Geneva, 6 December 2017 — The Medicines Patent Pool Governance Board has appointed Patrizia Carlevaro, co-founder of the technology company GenomSys, as a new board member, effective 1 December. Dr. Carlevaro, formerly Managing Director of Otsuka and Head of the International AID Unit at Eli Lilly and Company in Geneva, has had a long, distinguished career in public health, specifically in the research and development-based pharmaceutical industry. At Otsuka, she was responsible for subsidiary operations and the anti-infective business unit’s public health projects. At Lilly, where she served for almost a decade, Dr. Carlevaro developed and managed the company’s global Multidrug-Resistant Tuberculosis (MDR-TB) Partnership programme, conducting transfer of technology programmes for TB compounds to local manufacturers in China, India, South Africa and Russia.
“We are pleased to welcome Patrizia to the MPP Governance Board,” said Marie-Paule Kieny, Chair of the Board. “With her many years of experience in pha...
1 December 2017
Greg Perry, Executive Director
This World AIDS Day, we are pleased to acknowledge the international community’s progress in ensuring that people living with HIV have the tools necessary to lead long, healthy lives. Last week, UNAIDS reported a record 20.9 million people are now accessing antiretroviral therapy, a threefold increase since Unitaid created the MPP in 2010 to support the HIV response. The MPP is proud of the part it has played over the years to improve the availability of low-cost, high-quality medicines in low- and middle-income countries. To date, our generic partners have distributed more than five billion doses of WHO-recommended antiretrovirals, the equivalent of 14 million patient years of treatment.
This past year, we also welcomed our partners steps to produce, register and rollout new HIV treatment regimens that could be game changers in advancing standard of care. Sixteen companies are currently developing new HIV treatment dolutegravir (DTG), an easily admi...
Geneva, 02 November 2017 — The Medicines Patent Pool and the United States Agency for International Development (USAID) signed a Memorandum of Understanding (MoU) to accelerate the introduction of quality, affordable new medicines for diseases that disproportionately affect developing countries.
The two parties currently collaborate as part of the OPTIMIZE consortium, supported by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) and dedicated to rapidly improving treatment outcomes for people living with HIV in low- and middle-income countries.
The USAID-MPP partnership aims to facilitate the development and early introduction of better-formulated antiretrovirals, including those prioritized by OPTIMIZE. The MPP and USAID will coordinate efforts on market intelligence, supplier engagement and technical support in key PEPFAR countries. The MoU also envisions the two parties working together in other areas to address access to medicines issues for HIV as well as for other select diseases in th...
“Successful cooperation of the Ministry of Health of Belarus with the Medicines Patent Pool is crucial in light of our current work to achieve the “90-90-90” goals and put an end to the epidemic in the country which is only possible when access to affordabl...”